Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TrilynX phase 3 trial of xevinapant plus cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma
MOH_2020-12-28_009613Phase 3Recruiting
- Sponsor
- Merck KGaA
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Xevinapant arm with Placebo arm (2 arms). Started Sep 2020; status: recruiting.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2020-12-28_009613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-28_009613.